NCT07042438View on ClinicalTrials.gov

Fecal Microbiome Transplant to Remodel Intestinal Microbiota for Patients With Relapsed or Refractory Lymphoma With Exposure to High-Risk Antibiotics Who Are Receiving Chimeric Antigen Receptor T Cells

PHASE2Not yet recruitingINTERVENTIONAL
Enrollment

56

Participants

Timeline

Start Date

January 17, 2026

Primary Completion Date

April 13, 2028

Study Completion Date

April 13, 2028

Conditions
Recurrent Diffuse Large B-Cell LymphomaRecurrent High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 RearrangementsRecurrent Transformed Follicular Lymphoma to Diffuse Large B-Cell LymphomaRefractory Diffuse Large B-Cell LymphomaRefractory High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 RearrangementsRefractory Transformed Follicular Lymphoma to Diffuse Large B-Cell Lymphoma
Interventions
BIOLOGICAL

Axicabtagene Ciloleucel

Given CAR-T cells

PROCEDURE

Biospecimen Collection

Undergo blood sample collection

DRUG

Chemotherapy

Receive chemotherapy

PROCEDURE

Fecal Microbiota Transplantation

Given PO

PROCEDURE

Leukapheresis

Undergo leukapheresis

DRUG

Placebo Administration

Given PO

Trial Locations (1)

91010

City of Hope Medical Center, Duarte

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

City of Hope Medical Center

OTHER